FDA授予elranatamab-bcmm加速批准用于多发性骨髓瘤
正文 · 中文译文
FDA加速批准elranatamab-bcmm用于多发性骨髓瘤 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已核实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2023年8月14日,美国食品药品监督管理局(FDA)加速批准elranatamab-bcmm(Elrexfio,辉瑞公司),一种靶向B细胞成熟抗原(BCMA)的双特异性CD3 T细胞衔接器,用于既往至少接受过四线治疗(包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体)的复发或难治性多发性骨髓瘤成人患者。 查看Elrexfio完整处方信息。 疗效在MagnetisMM-3(NCT04649359)中评估,该研究为一项开放标签、单臂、多中心研究,纳入对至少一种蛋白酶体抑制剂、一种免疫调节药物和一种抗CD38抗体难治的复发/难治性多发性骨髓瘤患者。患者入组时经国际骨髓瘤工作组(IMWG)标准判定具有可测量疾病。 主要疗效结局指标为客观缓解率(ORR)和缓解持续时间(DOR),由盲态独立中心审查根据IMWG标准进行评估。主要疗效人群包括97例既往未接受过BCMA靶向治疗且既往至少接受过4线治疗(包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体)的患者。在接受推荐剂量的97例患者中,ORR为57.7%(95% CI:47.3%,67.7%)。在缓解者中位随访11.1个月时,中位DOR未达到(95% CI:12个月,未达到)。6个月时DOR率为90.4%(95% CI:78.4%,95.9%),9个月时为82.3%(95% CI:67.1%,90.9%)。 elranatamab-bcmm的处方信息包含一项黑框警告,警示危及生命或致命的细胞因子释放综合征(CRS)和神经毒性,包括免疫效应细胞相关神经毒性(ICANS)。在接受推荐剂量elranatamab-bcmm的患者中,58%的患者发生CRS,59%发生神经毒性,3.3%发生ICANS。0.5%的患者发生3级CRS,7%发生3级或4级神经毒性。 由于CRS和神经毒性(包括ICANS)的风险,elranatamab-bcmm仅可通过一项名为ELREXFIO REMS的风险评估与缓解策略(REMS)下的限制性项目获得。 最常见的不良反应(≥20%)为细胞因子释放综合征(CRS)、疲乏、注射部位反应、腹泻、上呼吸道感染、肌肉骨骼疼痛、肺炎、食欲减退、皮疹、咳嗽、恶心和发热。最常见的3至4级实验室异常(≥20%)为淋巴细胞减少、中性粒细胞减少、血红蛋白降低、白细胞减少和血小板减少。 elranatamab-bcmm的推荐剂量包括以下内容:第1天“递增剂量1”12 mg,第4天“递增剂量2”32 mg,随后第8天给予首次治疗剂量76 mg,此后每周76 mg,直至第24周。对于已接受至少24周elranatamab-bcmm治疗且达到部分缓解或更佳疗效并维持缓解至少2个月的患者,给药间隔应过渡为每两周一次方案。elranatamab-bcmm可持续使用直至疾病进展或出现不可接受的毒性。 本审评在Project Orbis框架下开展,该项目是美国FDA肿瘤卓越中心的一项倡议。Project Orbis为国际合作伙伴之间肿瘤药物的同步提交和审评提供了框架。本次审评中,FDA与澳大利亚治疗用品管理局(TGA)、巴西卫生监管局(ANVISA)、加拿大卫生部以及瑞士 Swissmedic 合作。其他监管机构的申请审评仍在进行中。 本审评使用了Assessment Aid,这是申请人自愿提交以促进FDA评估的材料。 该申请获得了优先审评、突破性疗法认定和孤儿药认定。FDA的加快审评程序在《行业指南:严重疾病-药物和生物制品的加快审评程序》中有所描述。 医疗保健专业人员应将所有怀疑与任何药物和器械使用相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需协助申请研究性肿瘤产品的单患者IND,医疗保健专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 在X(原Twitter)上关注肿瘤卓越中心 @FDAOncology。 内容截至日期: 08/14/2023 受监管产品 药物 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On August 14, 2023, the Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. View full prescribing information for Elrexfio. Efficacy was evaluated in MagnetisMM-3 (NCT04649359), an open-label, single-arm, multi-center study that included patients with relapsed/refractory MM who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. Patients had measurable disease by International Myeloma Working Group (IMWG) criteria at enrollment. The main efficacy outcome measures were objective response rate (ORR) and duration of response (DOR), as assessed by a blinded independent central review based on IMWG criteria. The primary efficacy population consisted of 97 patients naïve to prior BCMA-directed therapy and who had previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The ORR in the 97 patients receiving the recommended dose was 57.7% (95% CI: 47.3%, 67.7%). With a median follow-up of 11.1 months among responders, the median DOR was not reached (95% CI: 12 months, not reached). The DOR rate at 6 months was 90.4% (95% CI: 78.4%, 95.9%) and at 9 months was 82.3% (95% CI: 67.1%, 90.9%). The prescribing information for elranatamab-bcmm has a Boxed Warning for life threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS). Among patients who received elranatamab-bcmm at the recommended dose, CRS occurred in 58% of patients, neurologic toxicity in 59%, and ICANS in 3.3%. Grade 3 CRS occurred in 0.5% of patients and Grade 3 or 4 neurologic toxicity occurred in 7%. Because of the risks of CRS and neurologic toxicity, including ICANS, elranatamab-bcmm is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the ELREXFIO REMS. The most common adverse reactions (≥20%) were CRS, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased white blood cells, and decreased platelets. The recommended elranatamab-bcmm dosages include the following: “step-up dose 1” of 12 mg on Day 1, “step-up dose 2” of 32 mg on Day 4, followed by the first treatment dose of 76 mg on Day 8, and then 76 mg weekly, thereafter, through week 24. For patients who have received at least 24 weeks of elranatamab-bcmm and have achieved partial responses or better and maintained responses for at least 2 months, the dose interval should transition to an every two-week schedule. Elranatamab-bcmm may be continued until disease progression or unacceptable toxicity. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, and Switzerland’s Swissmedic. The application reviews are ongoing at the other regulatory agencies. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted priority review, breakthrough designation and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology. Content current as of: 08/14/2023 Regulated Product(s) Drugs Oncology